Failure to launch.

The article focuses on the generic at-risk launches in the U.S. and examines their impact on pharmaceutical patent litigations. It notes that the utmost concern to the product innovator in a pharmaceutical company is the potential for generic competition before patent expiration. It mentions that an innovator's best strategy to prevent a generic at-risk launch is to find a favorable trial decision before termination of the 30-month stay.